Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 5/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 5/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923368 | 0.86 | PPARG (0.45) | PPARGTHRBSMN1; SMN2MAPTTP53 | |
| SCHEMBL3011907 | 0.83 | PPARG (0.42) | ELANEPPARGTHRBSMN1; SMN2SLC5A1 | |
| SCHEMBL4917307 | 0.83 | PPARG (0.45) | ELANEPPARGSLC5A1SLC5A2PPARA | |
| SCHEMBL3010781 | 0.82 | ELANE (0.44) | ELANEPPARGTHRBSMN1; SMN2SLC5A1 | |
| SCHEMBL3575288 | 0.80 | PTGES (0.44) | PPARGTHRBSMN1; SMN2MAPTTP53 | |
| SCHEMBL4918420 | 0.80 | PPARG (0.43) | PPARGPPARA | |
| SCHEMBL4698400 | 0.79 | PTGES (0.45) | PPARGTHRBSMN1; SMN2MAPTTP53 | |
| SCHEMBL4916920 | 0.79 | ELANE (0.41) | ELANEPPARGTHRBSMN1; SMN2SLC5A1 | |
| SCHEMBL4918614 | 0.77 | PPARG (0.47) | PPARGPPARA | |
| SCHEMBL4925664 | 0.77 | PTGES (0.39) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-10-09 | — | — | US | disclosed |
| EP-1844013-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006077364-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, ARG1 | ELANE 648/4885PPARG 2586/4885THRB 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.